Top Line: Have you ever thought much, or at all, about immunotherapy dosing and what is to be gained or lost with dose reductions?
The Study: As opposed to weight-based dosing often used with chemo, nivolumab is largely delivered in a flat dose at 240 mg q2 weeks across virtually all indications. The reasons that allow for this much-simplified dosing are the same ones that could mean we’re often delivering far more than is needed: receptor saturation occurs at very low doses (up to 70% with 0.3 mg/kg, or 22.5 mg for a 75 kg individual), low variability in patient clearance, and–related to all this–very wide therapeutic windows. Tata Memorial is at it again with another brilliantly pragmatic phase 3 trial that evaluated ultra-low dose nivo at 20 mg q2 weeks versus physician’s choice chemo among 500 patients with solid tumors (88% head and neck or lung primaries) progressing within 6 months of first-line systemic therapy. Overall survival at one year significantly favored ultra-low dose nivo (27.3%) versus chemo (16.9%) with longer median duration of response (8 versus 5 months). The only immediate application here is that low-income countries can now treat 10x as many patients with the same finite limited supply. But it also brings up several fascinating questions in the context of many musings that prolonged or indefinite immunotherapy may not be warranted. How does prolonged standard dosing compare to prolonged ultra-low dosing or, even more intriguing, standard induction dosing followed by ultra-low dosing maintenance? And how might this all interplay with concurrent chemotherapy and/or (yes, we’re going to ask!) radiotherapy..?
TBL: Several strategies for immunotherapy total dose de-escalation remain ripe for investigation. | Noronha, J Clin Oncol 2026
The Study: As opposed to weight-based dosing often used with chemo, nivolumab is largely delivered in a flat dose at 240 mg q2 weeks across virtually all indications. The reasons that allow for this much-simplified dosing are the same ones that could mean we’re often delivering far more than is needed: receptor saturation occurs at very low doses (up to 70% with 0.3 mg/kg, or 22.5 mg for a 75 kg individual), low variability in patient clearance, and–related to all this–very wide therapeutic windows. Tata Memorial is at it again with another brilliantly pragmatic phase 3 trial that evaluated ultra-low dose nivo at 20 mg q2 weeks versus physician’s choice chemo among 500 patients with solid tumors (88% head and neck or lung primaries) progressing within 6 months of first-line systemic therapy. Overall survival at one year significantly favored ultra-low dose nivo (27.3%) versus chemo (16.9%) with longer median duration of response (8 versus 5 months). The only immediate application here is that low-income countries can now treat 10x as many patients with the same finite limited supply. But it also brings up several fascinating questions in the context of many musings that prolonged or indefinite immunotherapy may not be warranted. How does prolonged standard dosing compare to prolonged ultra-low dosing or, even more intriguing, standard induction dosing followed by ultra-low dosing maintenance? And how might this all interplay with concurrent chemotherapy and/or (yes, we’re going to ask!) radiotherapy..?
TBL: Several strategies for immunotherapy total dose de-escalation remain ripe for investigation. | Noronha, J Clin Oncol 2026